Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Bruton tyrosine kinase (BTK) plays a functional and integral role in B-cell receptor (BCR) signalling and is expressed in normal and malignant B cells. Given BTK’s central role in the survival and proliferation of malignant B cells, BTK inhibitors have been developed for use in various B-cell malignancies, with several US Food and Drug Administration approvals in […]

Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 15th 2018

In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma.

Questions:

1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European approval of encoranefib plus binimetanib for BRAF-mutant metastatic melanoma? (0:11)

2. What are the advantages of this combination compared with other combined BRAF/MEK inhibitor therapies? (1:25)

3. What are the best treatment options for patients whose disease progresses on this therapy? (2:41)

4. How can we prevent or overcome resistance to BRAF/MEK inhibitors? (3.18)

5. How is the approval of this combined therapy likely to impact on clinical practice? (4:24)

Speaker disclosures: Dirk Schadendorf has nothing to disclose in relation to this interview.

Filmed at the European Society for Medical Oncology (ESMO) congress, Germany, 19–23 October 2018

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup